The purpose of this study is to test therapeutic benefits of take-home LAAM. (1) Do subjects with take-home LAAM availability show increased clinical responsibility over subjects without; (2) Do subjects with take-home LAAM attempt diversion when random recall and other diversion safeguards are used; (3) Does treatment response correlate with background or drug use variables at intake, discharge, or during treatment?
Feasibility Study of Take-Home LAAM Medication – 3
Medical trial
ClinicalTrials.gov Identifier:
- NCT00000300
Sponsor:
Type of trial:
Design:
Primary outcomes:
- Drug Use
- Decreased frequency of HIV related behavior
- Increased prosocial behaviors
- Retention
Start date:
- Mar 1995
Phase:
Minimum age for eligibility:
- 18
Eligibility inclusion criteria:
- Meets DSM-IV criteria for opiate dependence
- Willing to provide names, addresses, and numbers of 3 relatives who can aid in patient location for follow-up visits
- Able to understand English
- Certified for LAAM treatment by a physician
Eligibility exclusion criteria:
- Hypertensive to LAAM
- Female of childbearing potential who refuses to use an acceptable form of birth control
- Pregnant or nursing women
- Medical or psychiatric illness which would jeopardize safe study participation
- Clinically significant abnormality in hematology, blood work, or UA, ETOH and/or sedative/hypnotic dependence according to DSM-IV criteria
Location:
Health authority:
Diseases:
Treatment being tested:
You can help improve this topic by adding more facts here